Witnesses stunned as small meteor lights up sky over parts of Western Australia
Many early risers from Perth to the central Wheatbelt took to social media on Sunday morning to report seeing a "fireball" tear through the sky just before 6am.
The appearance of the light was recorded by surveillance cameras operated by the Perth Observatory.
"It looks like it may have entered the atmosphere over the Central Wheatbelt heading from the north to the south around 5:57 am," the observatory's Matthew Woods said.
"It's most likely an iron meteor that's been orbiting within the inner Solar System."
Mr Woods said said the meteor would have heated up because of the friction caused when it came through the atmosphere.
"And that's where you're getting to see that lovely green, orange glow.
"We're very lucky it happened just before sunrise."
He estimated it to be anywhere between the size of a cricket ball to the size of a basketball.
Mr Woods could not confirm if the meteor landed somewhere in WA or it exploded but said experts within a wide network would be looking into it.
He said while the fireball coincided with the Eta Aquarids meteor shower, it was probably not part of the cosmic occurrence due to its size.
"The ETA Aquarians are caused by the tail of Comet Halley, we're talking about the crumbs off the tail, like ice particles and dust particles, they're very, very small.
"It could be one of these things where it's a coincidence."
Curtin University astrophysicist Steven Tingay dismissed claims by some observers that the fireball was the Soviet-era spacecraft, Kosmos 482.
The Kosmos 482 lander made an uncontrolled re-entry over the Indian Ocean on Saturday, but European and US agencies were unsure where it ended up.
Based on social media videos and eyewitness reports, the meteor resembled a brilliant fireball.
"I saw this as I'm driving a truck near Gingin at 5.50am, I was admiring the sky when this ball of light flashed across the sky. Never seen anything like it," wrote Chris Holgate.
Caroline Burton wrote that it was "so incredibly special to witness, I was on my way to work through Scarborough, and it shot past what felt like right in front of me".
"I saw it from Mt Magnet WA at about 6am. It was so big & bright, that I initially thought that it was the moon until it moved," wrote Tracey Johnstone.
"It was huge and burning bright orange red."
Mr Woods said witnessing a fireball in the sky was rare is because the Earth was 70 per cent ocean.
"Earth gets hit by about 100 tonnes of material each year, so most of these really bright ones happen over ocean or while we sleep, so that's why it's good to have night cameras."
He said the event was a nice Mother's Day surprise.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Sydney Morning Herald
3 days ago
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

The Age
3 days ago
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.


West Australian
3 days ago
- West Australian
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes. The cells have been used many times over the years via early-phase clinical trials, studies and on compassionate grounds, with promising results. Later in the year, NeuroScientific expects to receive the interim results from its latest compassionate access program involving patients with difficult-to-treat fistulising Crohn's disease, in which an open wound develops from a gut flare-up that extends out to the skin. A successful clinical outcome will help the company validate its proprietary StemSmart technology in this patient group, which otherwise has limited treatment options. NeuroScientific is fast building towards regulatory approvals and commercialisation for StemSmart. This month, it announced two heavy-hitting appointments. The company has appointed Melbourne-based Smith's as its chief executive officer and well-regarded Perth-based paediatric haematologist and oncologist Dr Catherine Cole as its chief medical officer. Smith has extensive experience in cell and gene therapies in senior commercial, operational and strategic roles in Australia and the United States, which should prove invaluable as the company navigates the regulatory and commercial pathways for its innovative StemSmart technology. The company says Smith's deep expertise in good manufacturing practice (GMP) will be critical for converting the biotechnology startup into a scaled-up commercial stem cell company. Cole has held clinical and academic leadership roles across Australia and overseas, including head of haematology and oncology at Perth Children's Hospital and professor of paediatric haematology and oncology at The University of Western Australia. She is also the former director of stem cell transplantation at Perth Children's Hospital, placing her front and centre in NeuroScientific's race to employ stem cell therapy to treat some of the most debilitating transplant complications and autoimmune diseases. The high-level executive duo join a strong leadership team, which also includes Perth-based haematology medical scientist Dr Marian Sturm as NeuroScientific's chief scientific officer. Sturm pioneered the use of the MSC used in StemSmart over the past 20 years in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. While competition in the stem cell space is fierce, the upside is enormous. StemSmart's progress and results over decades of development position the product closer to near-term commercialisation than some others also in the pipeline, which will be helped along by NeuroScientific's healthy bank balance. A $3.5 million capital raise handed the company a $7.5 million war chest to support further trials and development and help it generate plenty of momentum towards its long-term goal of partial or full registration for StemSmart, first up as a Crohn's treatment. NeuroScientific's progress in the field of stem cell therapy has certainly got the tongues wagging recently. The soaring share price has hardly taken a breather, clocking in with an eye-watering 360 per cent rise to 23.5 cent a share in the last two months alone. As StemSmart edges closer to regulatory approval and potential commercial rollout starts to take shape - starting with the pressing need in Crohn's disease - NeuroScientific appears poised to carve out a meaningful niche in the high-stakes world of advanced cell therapies. Is your ASX-listed company doing something interesting? Contact: